Cargando…

Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study

BACKGROUND: Multiple sclerosis (MS) currently requires long-term treatment with disease-modifying drugs, administered parenterally up to once daily. The need for regular self-injection can be a barrier to treatment for many patients. Autoinjectors can help patients overcome problems or concerns with...

Descripción completa

Detalles Bibliográficos
Autores principales: Devonshire, Virginia, Arbizu, Txomin, Borre, Björn, Lang, Michael, Lugaresi, Alessandra, Singer, Barry, Verdun di Cantogno, Elisabetta, Cornelisse, Peter
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2877661/
https://www.ncbi.nlm.nih.gov/pubmed/20433746
http://dx.doi.org/10.1186/1471-2377-10-28
_version_ 1782181795364601856
author Devonshire, Virginia
Arbizu, Txomin
Borre, Björn
Lang, Michael
Lugaresi, Alessandra
Singer, Barry
Verdun di Cantogno, Elisabetta
Cornelisse, Peter
author_facet Devonshire, Virginia
Arbizu, Txomin
Borre, Björn
Lang, Michael
Lugaresi, Alessandra
Singer, Barry
Verdun di Cantogno, Elisabetta
Cornelisse, Peter
author_sort Devonshire, Virginia
collection PubMed
description BACKGROUND: Multiple sclerosis (MS) currently requires long-term treatment with disease-modifying drugs, administered parenterally up to once daily. The need for regular self-injection can be a barrier to treatment for many patients. Autoinjectors can help patients overcome problems or concerns with self-injection and could, therefore, improve treatment adherence. This study was performed to assess the suitability of a new electronic device for the subcutaneous (sc) administration of interferon (IFN) beta-1a, 44 mcg three times weekly, for relapsing MS. METHODS: In this Phase IIIb, multicentre, single-arm study, patients with relapsing MS who had been consistently self-injecting sc IFN beta-1a using an autoinjector for at least 6 weeks were taught to use the new device and self-administered treatment for 12 weeks thereafter. Patient-rated suitability of the device was assessed at the end of Week 12 using the Patient User Trial Questionnaire. Patient satisfaction with, and evaluation of, the injection process was assessed using the MS Treatment Concern Questionnaire. Trainers evaluated the device using the Trainer User Trial Questionnaire. RESULTS: At Week 12, 71.6% (73/102) of patients considered the device 'very suitable' or 'suitable' for self-injection; 92.2% (94/102) reported some degree of suitability and only 7.8% (8/102) found the device 'not at all suitable'. At Weeks 4, 8 and 12, most patients reported that injection preparation and clean-up, performing injections and ease of device use in the previous 4 weeks compared favourably with, or was equivalent to, their previous experience of self-injection. Injection-related pain, injection reactions and 'flu-like' symptoms remained stable over the 12 weeks. Each device feature was rated 'very useful' or 'useful' by at least 80% of patients. All trainers and 95.2% (99/104) of patients found device functions 'very easy' or 'easy' to use. Overall convenience was considered the most important benefit of the device. CONCLUSIONS: Most patients considered the new electronic injection device suitable for the sc injection of IFN beta-1a. They found the device easy to use with useful features, and reported benefits such as overall convenience. The device may, therefore, increase treatment adherence in patients with MS, particularly those with injection-related issues. TRIAL REGISTRATION: NCT00735007
format Text
id pubmed-2877661
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28776612010-05-27 Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study Devonshire, Virginia Arbizu, Txomin Borre, Björn Lang, Michael Lugaresi, Alessandra Singer, Barry Verdun di Cantogno, Elisabetta Cornelisse, Peter BMC Neurol Research article BACKGROUND: Multiple sclerosis (MS) currently requires long-term treatment with disease-modifying drugs, administered parenterally up to once daily. The need for regular self-injection can be a barrier to treatment for many patients. Autoinjectors can help patients overcome problems or concerns with self-injection and could, therefore, improve treatment adherence. This study was performed to assess the suitability of a new electronic device for the subcutaneous (sc) administration of interferon (IFN) beta-1a, 44 mcg three times weekly, for relapsing MS. METHODS: In this Phase IIIb, multicentre, single-arm study, patients with relapsing MS who had been consistently self-injecting sc IFN beta-1a using an autoinjector for at least 6 weeks were taught to use the new device and self-administered treatment for 12 weeks thereafter. Patient-rated suitability of the device was assessed at the end of Week 12 using the Patient User Trial Questionnaire. Patient satisfaction with, and evaluation of, the injection process was assessed using the MS Treatment Concern Questionnaire. Trainers evaluated the device using the Trainer User Trial Questionnaire. RESULTS: At Week 12, 71.6% (73/102) of patients considered the device 'very suitable' or 'suitable' for self-injection; 92.2% (94/102) reported some degree of suitability and only 7.8% (8/102) found the device 'not at all suitable'. At Weeks 4, 8 and 12, most patients reported that injection preparation and clean-up, performing injections and ease of device use in the previous 4 weeks compared favourably with, or was equivalent to, their previous experience of self-injection. Injection-related pain, injection reactions and 'flu-like' symptoms remained stable over the 12 weeks. Each device feature was rated 'very useful' or 'useful' by at least 80% of patients. All trainers and 95.2% (99/104) of patients found device functions 'very easy' or 'easy' to use. Overall convenience was considered the most important benefit of the device. CONCLUSIONS: Most patients considered the new electronic injection device suitable for the sc injection of IFN beta-1a. They found the device easy to use with useful features, and reported benefits such as overall convenience. The device may, therefore, increase treatment adherence in patients with MS, particularly those with injection-related issues. TRIAL REGISTRATION: NCT00735007 BioMed Central 2010-04-30 /pmc/articles/PMC2877661/ /pubmed/20433746 http://dx.doi.org/10.1186/1471-2377-10-28 Text en Copyright ©2010 Devonshire et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research article
Devonshire, Virginia
Arbizu, Txomin
Borre, Björn
Lang, Michael
Lugaresi, Alessandra
Singer, Barry
Verdun di Cantogno, Elisabetta
Cornelisse, Peter
Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study
title Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study
title_full Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study
title_fullStr Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study
title_full_unstemmed Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study
title_short Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study
title_sort patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, phase iiib study
topic Research article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2877661/
https://www.ncbi.nlm.nih.gov/pubmed/20433746
http://dx.doi.org/10.1186/1471-2377-10-28
work_keys_str_mv AT devonshirevirginia patientratedsuitabilityofanovelelectronicdeviceforselfinjectionofsubcutaneousinterferonbeta1ainrelapsingmultiplesclerosisaninternationalsinglearmmulticentrephaseiiibstudy
AT arbizutxomin patientratedsuitabilityofanovelelectronicdeviceforselfinjectionofsubcutaneousinterferonbeta1ainrelapsingmultiplesclerosisaninternationalsinglearmmulticentrephaseiiibstudy
AT borrebjorn patientratedsuitabilityofanovelelectronicdeviceforselfinjectionofsubcutaneousinterferonbeta1ainrelapsingmultiplesclerosisaninternationalsinglearmmulticentrephaseiiibstudy
AT langmichael patientratedsuitabilityofanovelelectronicdeviceforselfinjectionofsubcutaneousinterferonbeta1ainrelapsingmultiplesclerosisaninternationalsinglearmmulticentrephaseiiibstudy
AT lugaresialessandra patientratedsuitabilityofanovelelectronicdeviceforselfinjectionofsubcutaneousinterferonbeta1ainrelapsingmultiplesclerosisaninternationalsinglearmmulticentrephaseiiibstudy
AT singerbarry patientratedsuitabilityofanovelelectronicdeviceforselfinjectionofsubcutaneousinterferonbeta1ainrelapsingmultiplesclerosisaninternationalsinglearmmulticentrephaseiiibstudy
AT verdundicantognoelisabetta patientratedsuitabilityofanovelelectronicdeviceforselfinjectionofsubcutaneousinterferonbeta1ainrelapsingmultiplesclerosisaninternationalsinglearmmulticentrephaseiiibstudy
AT cornelissepeter patientratedsuitabilityofanovelelectronicdeviceforselfinjectionofsubcutaneousinterferonbeta1ainrelapsingmultiplesclerosisaninternationalsinglearmmulticentrephaseiiibstudy